Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
44
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer

Giandomenico Roviello1 Medical Oncology Unit, Department of Oncology, San Donato Hospital, Arezzo;2 Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, ItalyCorrespondence[email protected]
,
Silvia Paola Corona3 Radiation Oncology Department, Peter MacCallum Cancer Centre, Moorabbin Campus, East Bentleigh, VIC, Australia
,
Alberto Bonetta4 Radiotherapy Department
,
Maria Rosa Cappelletti5 Breast Cancer Unit, Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy
&
Daniele Generali2 Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy;5 Breast Cancer Unit, Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy
Pages 3811-3815 | Published online: 31 Jul 2017

References

  • AmlingCLBluteMLBergstralhEJSeayTMSlezakJZinckeHLong-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 yearsJ Urol2000164110110510840432
  • PotoskyALDavisWWHoffmanRMFive-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostatecancer outcomes studyJ Natl Cancer Inst2004961358136715367568
  • ChismDBHanlonALHorwitzEMFeigenbergSJPollackAA comparison of the single and double factor high risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapyInt J Radiat Oncol Biol Phys200459238038515145151
  • LeeAKD’AmicoAVUtility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapyJ Clin Oncol200523328192819716278472
  • MasonMDSydesMRGlaholmJOral sodium clodronate for nonmetastatic prostate cancer – results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)J Natl Cancer Inst2007991076577617505072
  • ZhangTArmstrongAJClinical utility of circulating tumor cells in advanced prostate cancerCurr Oncol Rep2016181326700506
  • de BonoJSScherHIMontgomeryRBCirculating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancerClin Cancer Res200814196302630918829513
  • StrijbosMHGratamaJWSchmitzPICirculating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxelEur J Cancer201046112027203520399640
  • GoodmanOBJrSymanowskiJTLoudyiAFinkLMWardDCVogelzangNJCirculating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancerClin Genitourin Cancer201191313821705286
  • ThompsonIThrasherJBAusGGuideline for the management of clinically localized prostate cancer: 2007 updateJ Urol200717762106213117509297
  • RoachMHanksGThamesHJrDefining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceInt J Radiat Oncol Biol Phys200665496597416798415
  • SlovinSFWiltonASHellerGScherHITime to detectable metastatic disease in patients with rising prostate specific antigen values following surgery or radiation therapyClin Cancer Res200511248669867316361552
  • ScherHIHellerGMolinaACirculating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancerJ Clin Oncol201533121348135525800753
  • GoldkornAElyBQuinnDICirculating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castrationresistant prostate cancerJ Clin Oncol201432111136114224616308
  • BrigantiASuardiNGallinaAPredicting the risk of bone metastasis in prostate cancerCancer Treat Rev201440131123896177
  • FranciniEPetrioliRRossiGLaeraLRovielloGPSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trialsTumour Biol20143511106011060725195134

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.